ADC Therapeutics S.A. (ADCT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-...
Analysis Summary
Trailing-twelve-month margins: gross margin 88.7%, operating margin -125.8%, net margin -123.0%.
At the current price of $1.05, ADCT has negative trailing earnings (P/E not meaningful) and an ROE of 44.63%. Market capitalisation stands at $134M.
Balance sheet quality for ADCT: current ratio of 4.4, net debt of $177.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.05 |
| Market Cap | $134M |
| Exchange | NYSE |
| Country | CH |
Valuation Ratios
| Price / Book | -0.56 |
| EV / EBITDA | -3.82 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 44.63% |
| Return on Invested Capital | -49.54% |
| Return on Assets | -34.69% |
| Gross Margin | 88.75% |
| Operating Margin | -125.83% |
| Net Margin | -123.03% |
Financial Health
| Debt / Equity | -1.83 |
| Current Ratio | 3.03 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -6.54 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADCT | ADC Therapeutics S.A. | $134M | 44.6% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +1.94% |
| 3 months | -3.67% |
| Year-to-date | -70.25% |
| 1 year | -67.69% |
| 3 years | +35.40% |
52-Week Range
| 52-week High | $4.98 |
| 52-week Low | $0.78 |
| Avg Volume (90d) | 1.8M |
Related companies: ALMS · AUTL · BCYC · FDMT · LCTX · LXRX · NMRA
Explore sector: Healthcare · Biotechnology
More sections of ADCT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks